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Insulin-like peptide 3 (INSL3), a major product of testicular Leydig cells, is also expressed by the
ovary, but its functional role remains poorly understood. Here, we quantified expression of INSL3
and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing
bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2mRNA levels were much higher
inTIC thangranulosacell and increasedprogressivelyduringfolliclematurationwith INSL3peaking
in large (11-18 mm) estrogen-active follicles and RXFP2 peaking in 9- to 10-mm follicles before
declining in larger (11-18 mm) follicles. Expression of both INSL3 and RXFP2 in CL was much lower
than in TIC. In situ hybridization and immunohistochemistry confirmed abundant expression of
INSL3 mRNA and protein in TIC. These observations indicate follicular TIC rather than CL as the
primary site of both INSL3 production and action, implying a predominantly autocrine/paracrine
role in TIC. To corroborate the above findings, we showed that in vitro exposure of TIC to a
luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptorwhile
increasing progesterone secretion and expression of STAR and CYP11A1. Moreover, in vivo, a
significant cyclic variation in plasma INSL3 was observed during synchronized estrous cycles. INSL3
andestradiol-17 followeda similar pattern, both increasingafter luteolysis, before falling sharply
after the LH surge. Thus, theca-derived INSL3, likely from the dominant preovulatory follicle, is
detectable in peripheral blood of cattle, and expression is down-regulated during luteinization
induced by the preovulatory LH surge. Collectively, these findings underscore the likely role of
INSL3 as an important intrafollicular modulator of TIC function/steroidogenesis, while raising
doubts about its potential contribution to CL function. (Endocrinology 154: 1897–1906, 2013)
Insulin-like peptide 3 (INSL3) is amember of the relaxin-insulin family of peptide hormones and is a major se-
cretory product of the testicular Leydig cells ofmalemam-
mals (1–3). In the adult male, it is produced in large
quantities, in a constitutive manner, and gives rise to sub-
stantial concentrations in the peripheral circulation. It is a
good marker for fully differentiated Leydig cells and is
likely to play a role inmaintaining spermatogenesis (2). In
the male fetus, INSL3 is an important product of the fetal
Leydig cells and is instrumental in the transabdominal
phase of testicular descent (4). Hence, the principal phe-
notype of male Insl3 knockout mice is primary cryp-
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torchidism (5, 6). INSL3 signals through a G protein-cou-
pled receptor known as relaxin family peptide receptor
(RXFP)2 (7), which is closely related to the relaxin recep-
tor RXFP1. Mice lacking RXFP2 exhibit the same cryp-
torchid phenotype as that of Insl3 knockout mice (8, 9).
Although INSL3 has principally been described as a
male hormone, it is also expressed in the adult female, by
follicular theca cells and corpus luteum (CL) of the ovary
(10–16). The role of INSL3 in the female is not well de-
fined. However, there is evidence to suggest that it is in-
volved inpostpubertal follicular selectionandmaturation.
INSL3 knockout mice have been found to display im-
paired fertility and have higher rates of follicular atresia
and fewer ovulations than their wild-type littermates (5,
17). It has been suggested that INSL3 is a marker of dif-
ferentiated theca cells and can be modulated by factors
that influence follicle differentiation, such as IGF, insulin,
and LH (14, 18). Levels have also been shown to decline
in atretic follicles (14).
INSL3 has been detected in the peripheral blood of
adult women but at much lower levels than in men (19,
20), perhaps indicating that it plays a local intraovarian
role rather than a systemic endocrine role in the female (2).
However, in ruminants, ovarian expression levels are con-
siderably higher than in other mammals, and this may
indicate that it also plays a systemic role in these species
(11, 18).
The aims of the present study were, firstly, to perform
a detailed analysis of the expression of INSL3 and its re-
ceptor RXFP2 in bovine ovarian follicles, spanning key
stages of antral follicle development, including cyclic re-
cruitment, selection/deviation, luteinizing hormone/cho-
riogonadotropin receptor (LHCGR) acquisition, and
dominance, in order to further define the role of INSL3
during follicle development and to identify the target of its
action. Secondly, we examined expression of INSL3 and
RXFP2 in luteal tissue. Thirdly, bovine theca interna
cells (TICs) in primary culture were used to determine
the effect of LH-induced luteinization on expression of
INSL3 and RXFP2. Finally, circulating plasma levels of
INSL3 throughout the bovine oestrus cycle were mea-
sured for the first time using a recently developed time-
resolved fluorescence immunoassay (21) in order to ex-
amine whether there is cyclic variation in INSL3 and to
correlate this information with the results from the




Ovaries fromnonpregnant adult cattle slaughteredat random
stages of the estrous cycle were collected from a local abattoir.
They were transported to the laboratory in medium-199 sup-
plementedwith1%(vol/vol) antibiotic antimycotic solution. For
in situ hybridization, ovaries were snap frozen in isopentane on
dry ice immediately after collection. For immunohistochemistry,
fresh follicular tissues were immersion fixed in Bouin’s fixative
for 6 hours, followed by graded ethanols and embedding in par-
affin wax. As control tissues, testis fragments from sexually ma-
ture animals were similarly processed.
Preparation of granulosa cell (GC) and TIC extracts
for gene expression analysis
Follicles ranging in diameter from 1 to 18mmwere dissected
from ovaries that were judged to be from cattle in the mid to
late-luteal phase, as described in detail elsewhere (22). Estima-
tion of cycle stage was based on the morphological appearance
of the CL (23). Follicles were sorted by size, and their GC, TIC
layers, and follicular fluid were recovered. Isolated GCs and
TICswere homogenized in 0.5mL of Trireagent (SigmaUKLtd,
Poole, United Kingdom) and stored at 80°C before RNA ex-
traction. Concentrations of estradiol-17 (E2) and progesterone
in follicular fluid were determined by immunoassay. Follicles in
the largest size category (11–18mm) were subdivided according
to their follicular fluid E2 to progesterone (P4) ratio, with those
with E2 to P4 ratio more than 1 being presumed healthy, “es-
trogen-active” dominant follicles, and those with E2 to P4 ratio
less than 1 being presumed to be “estrogen inactive” and
regressing (22).
Isolation of CL samples for gene expression
analysis
Samples of CL tissue were isolated from the ovaries and were
categorized as being “early-luteal,” “midluteal,” and “late-lu-
teal” phase, according to the criteria described by Ireland et al
(23). CL samples were snap frozen on dry ice and stored at
80°C before subsequent RNA extraction using Trireagent.
In vitro TIC luteinization model
TICs were isolated from the ovaries as described previously
(24). For each experiment, TICs were pooled from around 50
follicles of 4–6 mm in diameter and were plated at a density of
500 000 viable cells/well in 24-well plates (Nunclon, Life Tech-
nologies Ltd, Carlsbad, California). Serum-free culture medium
was used throughout:McCoy’s 5Awith 1% (vol/vol) antibiotic-
antimycotic solution, 10-ng/mL bovine insulin, 2mM L-glu-
tamine, 10mM HEPES, 5-mg/mL apotransferrin, 5-ng/mL so-
dium selenite, and 0.1% (wt/vol) BSA. Cells were cultured for 6
days (removing and replacing with fresh media every 48 h) at
38.5°C in the presence or absence of a luteinizing dose level (1.5
ng/mL) of ovine LH (NIADDK oLH-S16; obtained fromNHPP,
Torrance, California). At the end of the culture, conditioned
media were retained for P4 and INSL3 immunoassays, and cell
lysates were prepared using the lysis buffer supplied with the
RNeasy extraction kit (Buffer RLT; QIAGEN Ltd, Manchester,
United Kingdom), according to the manufacturer’s instructions.
Lysates from replicate wells were pooled and stored at 80°C
before RNA extraction. The experiment was repeated 4 times
with independent batches of ovaries.
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In vivo studies in prostaglandin (PG)-synchronized
heifers
The 5 British Friesian heifers (2 y old; 400-kg body
weight) used in this study were housed indoors, loosely tethered
in individual stands. They were fed amaintenance ration of con-
centrates and straw and had continual access to water. Estrous
cycleswere synchronizedbygiving3 injections (im)of thePGF2
analog cloprostenol (0.5mg), 14 days apart. The day of the third
PG injection was designated as day 0 of the study. Two further
PG injections were given on days 14 and 28 to induce luteolysis,
resulting in 3 truncated cycles being studied per cow (n  15
cycles in total). Blood samples (50 mL) were taken on a daily
basis via a jugular vein catheter that was flushed with sterile
0.9%wt/vol saline containing sodiumheparin (100 IU/mL) after
sample withdrawal. Samples were collected into polypropylene
tubes containing 50 L of sodium heparin (5000 IU/mL). After
centrifugation (2000g for 30 min), plasma was decanted and
stored at 20°C awaiting hormone analysis. The experiment
was carried out in full compliance with United Kingdom Home
Office guidelines and the Animals (Scientific Procedures) Act
1986.
Does E2 directly alter expression of INSL3 or
RXFP2 expression by nonluteinized TIC?
To test whether direct exposure on nonluteinized TIC to E2
could affect expression ofmRNAs for INSL3orRXFP2, isolated
TICs were cultured with a concentration of LH (150 pg/mL)
conducive to optimal androstenedione secretion (24) in the pres-
ence and absence of E2 at a concentration (500 ng/mL) compa-
rable with that present in follicular fluid from preovulatory bo-
vine follicles. At the end of culture, conditioned media were
retained for androstenedione assay and cell lysates prepared for
RNA extraction and real-time PCR analysis. The experiment
was repeated 4 times with cells from independent batches of
ovaries.
E2, P4, and androstenedione immunoassays
Plasma E2 concentrations were determined by RIA as de-
scribed previously (25, 26), with an assay detection limit of 1.7
pg/mL and intra- and interassay coefficients of variation of 11%
and 15%, respectively. Concentrations of P4 in plasma and cell-
conditioned culturemediaweredeterminedbydirectELISA (27–
29). Intra- and interassay coefficients of variation were 9% and
13%, respectively, and the detection limitwas 20 pg/mL. Plasma
androstenedione levels were measures by ELISA as described
elsewhere (30). Before analysis, androstenedione was extracted
from the plasma using ethyl ether. Briefly, 5 volumes of ethyl
ether were added to 500-L plasma in glass tubes. Tubes were
vortexed for 1 minute and left to stand for 10 minutes to allow
the 2 phases to separate. The upper ethyl ether phase was trans-
ferred to a clean glass tube and allowed to evaporate to dryness.
The extracted steroid was then redissolved in assay diluent (PBS
containing 0.1%wt/vol gelatin and 0.05% vol/vol Proclin 300).
Androstenedione standards were made up in charcoal-stripped
cow plasma and were ether extracted in parallel with experi-
mental plasma samples. Androstenedione levels in the extracted
samples were then measured by competitive ELISA (30), using
the extracted standards to calibrate the assay, hence avoiding the
need to correct for recoveries. The goat antiandrostenedione anti-
body(IR637)usedintheassaywaskindlyprovidedbyDrG.S.Pope
(Institute for Grassland and Environmental Research, Hurley,
United Kingdom), and androstenedione-horseradish peroxidase
conjugate was purchased from Cal Bioreagents (Los Angeles, Cal-
ifornia). Intra- and interassay coefficients of variationwere7%and
12%, respectively.
INSL3 assay
Concentrations of INSL3 inplasmaandTIC-conditionedme-
dia were determined using a novel time-resolved fluorescence
immunoassay, which is highly specific for ruminant INSL3 and
is described in detail elsewhere (21). As tracer for the assay,
synthetic bovine INSL3 (A-chain/B-chain heterodimer) was la-
beled with (Eu3) chelate (see Supplemental Table 1, published
on The Endocrine Society’s Journals Online web site at http://
endo.endojournals.org). The assay detection range was from
0.02 to 20.0 ng/mL of bovine INSL3. Intra- and interassay co-
efficients of variation were 2% and 10%, respectively.
RNA isolation
Total RNA was isolated from TIC lysates using the RNeasy
kit (QIAGENLtd), according to themanufacturer’s instructions
and the RNA eluted in 30L of nuclease-free water. On-column
deoxyribonuclease (DNase) digestion was performed using ri-
bonuclease-free DNase (QIAGEN Ltd) to remove any potential
DNA contamination. Total RNAwas isolated from ex vivo GC,
TIC, and CL samples, using Trireagent (Sigma UK Ltd), as de-
scribed previously (22, 31), and potential genomic DNA con-
tamination was removed with an ribonuclease-free DNase kit
(RQ1; Promega UK Ltd, Southampton, United Kingdom). RNA
quantity and quality were evaluated by spectrophotometry at
260/280 nm.
cDNA synthesis and real-time PCR
cDNA was synthesized from 1 g of RNA using the Re-
verse-iT RT kit (Abgene, Epsom, United Kingdom) according to
the manufacturer’s instructions. Primers (see Table 1) were de-
signed using Primer Express software (version 1.5; PerkinElmer-
Applied Biosystems,Warrington, United Kingdom) and primer-
Table 1. List of Primers Used for Real-Time PCR
Target
Accession
number Forward primer 5 to 3 Reverse primer 5 to 3
Amplicon size
(base pairs)
STAR NM_174189 TTTTTTCCTGGGTCCTGACAGCGTC ACAACCTGATCCTTGGGTTCTGCACC 103
CYP11A1 NM_176644 CAGTGTCCCTCTGCTCAACGTCC TTATTGAAAATTGTGTCCCATGCGG 99
INSL3 NM_174365.2 TCTGTCCCCACTGAATCCTCCTGG GGGTTTCATGGTGCTGTGTGGC 102
RXFP2 XR_028620.2 CGAGGGCAGTATCAGAAGTACGCGC AGACCTCAGTGGACAGCATGGCC 91
ACTB NM_173979.3 ATCACCATCGGCAATGAGCGGTTC CGGATGTCGACGTCACACTTCATGA 128
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BLAST used to check in silico that no known bovine off-target
sequences would be amplified. Primer pairs were also validated
using agarose gel electrophoresis to demonstrate amplification
of a single product of the predicted size. In addition, post-PCR
dissociation curve analyses confirmed the amplification of a sin-
gle product in each sample. PCR amplification efficiencies for
ACTB, INSL3, RXFP2, STAR, and CYP11A1 were 97%,
100%, 100%, 92%, and 93%, respectively. PCR assays were
carried out in a total reaction volume of 14L, comprising 5-L
cDNA template, 1 L of each forward and reverse primer (final
concentration 0.36M) and 7-L QuantiTect SYBR Green
qPCR 2Master Mix (QIAGEN Ltd). Samples were processed
on an AB StepOne Plus real-time PCR instrument (Life Tech-
nologies, Paisley, United Kingdom) with cycling conditions: 15
minutes at 95°C (1 cycle only) followed by 15 seconds at 95°C
and 1 minute at 60°C for 40 cycles. The relative abundance of
each mRNA transcript was compared using the Ct method
(32). Threshold cycle (Ct) values for each transcript in a given
sample were first normalized to the -actin Ct value. It was con-
firmed that-actinwas a suitable reference control gene because
Ct values (16 cycles) were uniform across follicle size catego-
ries and cell types (P .1; data not shown). ForGC,TIC, andCL
samples, the resultant Ct values were then normalized to the
mean Ct value for the transcript in all the samples (ie, to gen-
erate Ct values). For TIC culture experiments, Ct values for
the samples treated with LH (1.5 ng/mL) were normalized to the
untreated control samples to generateCt values.Ct values
were subsequently converted to fold differences, for graphical
presentation, using the formula: fold difference  2Ct.
In situ hybridization
Frozen sections (25 m) were cut using a cryostat, thaw
mounted, and stored at 80°C until required. For in situ hy-
bridization sense and antisense riboprobes labeled with digoxy-
genin were synthesized by in vitro transcription with T7 and T3
RNA polymerase (Promega, Madison, Wisconsin) from nucle-
otides 96-431 of the INSL3 gene (accession number
NM_174365) cloned into pBluescript (Stratagene, La Jolla, Cal-
ifornia). After synthesis, the probeswere checked for integrity by
denaturing gel electrophoresis and purified using the RNeasy kit
(QIAGEN Ltd). Frozen slides were rapidly thawed and fixed for
20 minutes in 4% (wt/vol) paraformaldehyde in PBS at 4°C.
After proteinase K treatment (20 min at 37°C), sections were
hybridized overnight at 65°C with either the sense or antisense
riboprobe. After washing the sections, hybridized probe was de-
tected using an alkaline phosphatase-conjugated antidigoxyge-
nin antibody and visualized using NBT/BCIP alkaline phospha-
tase substrate (Roche Molecular Biochemicals, Indianapolis,
Indiana). Cryostat sections of frozen bovine testis were included
as a positive control, and sense probes were included to deter-
mine nonspecific background labeling.
Immunohistochemistry
Eight-micrometer paraffin sections of bovine follicular and
testis tissues were dewaxed and subjected to immunohistochem-
istry after the double peroxidase-antiperoxidase-avidin-biotin-
complex protocol as previously described (33), with diamino-
benzidine (Sigma UK Ltd) as chromogen. As primary antibody,
the polyclonal antiserum (AS 33) raised in rats against a recom-
binant bovine pro-INSL3 protein made in Escherichia coli was
used, as previously described and validated (14), at a dilution of
1:1000. Sections were briefly counterstained using Light Green
and mounted in aqueous mounting medium.
Statistical analysis
Real-time PCR data were analyzed as Ct values before con-
version to fold difference values, and results were analyzed using
1- or 2-wayANOVA. Post hoc pairwise comparisons referred to
in results were made by Fisher’s protected least significant dif-
ference (PLSD) test. For in vitro experiments, results presented
are combined data from 4 independent cultures. Statistical anal-
ysis of plasma hormone concentrations was performed by re-
peated measures ANOVA. Providing a significant “F’ ratio was
recorded post hoc Fisher’s PLSD test was used for individual
pairwise comparisons between different time points.
Results
Changes in INSL3 and RXFP2 mRNA expression in
developing follicles and in CL
Mean Ct values for ACTB (-actin), INSL3, and
RXFP2 were, respectively, 16.1, 16.8, and 25.5 for TIC,
15.3, 20.5, and 31.9 for GC, and 15.6, 21.3, and 33.4 for
CL samples. As shown in Figure 1, the relative abundance
of mRNA for INSL3 and its receptor RXFP2 was much
greater in TIC than GC across all follicle size categories
(2-way ANOVA effect of cell type: INSL3, P  .001;
RXFP2, P .0001). Levels of both transcripts varied sig-
nificantly according to follicle size (2-way ANOVA effect
of size class: INSL3, P  .05; RXFP2, P  .001). INSL3
Figure 1. Relative abundance of mRNA transcripts for INSL3 and its
receptor RXFP2 in the thecal and granulosal compartments of varying
sizes of developing bovine antral follicles. Follicles in the largest size
category (11-18 mm) were subdivided according to whether they were
estrogen active, with an estrogen to progesterone ratio of greater than
1 (EP  1) or estrogen inactive (EP  1). Values are means (	SEM),
and results of 2-way ANOVA are summarized.
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mRNA level in the TIC layer showed a progressive 5-fold
increase as follicles developed from 1-2 to 11-18 mm and
was greatest in the 11- to 18-mm estrogen-active follicles.
Expression level was approximately 50% lower in estro-
gen inactive than estrogen-active follicles of this size cat-
egory (P .05; post hoc PLSD test).RXFP2 expression in
TICalso increased as follicles developed from1–2 to 9–10
mm, before decreasing again in both estrogen-active and
estrogen-inactive 11- to 18-mm follicles. There was a
highly significant positive correlation (r 0.81, P .001,
n 47) between the relative mRNA abundance of INSL3
and CYP17 in the TIC compartment of follicles of 1–18
mm in diameter (Figure 2).
INSL3 and RXFP2 were also expressed in CL tissue
(Figure 3), with the relative expression of INSL3 being
significantly higher in the midluteal stage than in regress-
ing CL samples (P  .05). However, relative to -actin,
levels of INSL3mRNAweremuch lower inCL tissue than
in follicular TIC samples (6- to 30-fold lower depending
on follicle size class used for comparison).
In situ hybridization: localization of INSL3 mRNA
in ovary sections
ThemRNAexpressiondata above showing that INSL3
wasmainly expressed in the thecal compartment was con-
firmed by in situ hybridization. Figure 4A shows that the
intensity of staining for INSL3mRNA was much greater
in the theca layer, with little staining in the GC layer or
surrounding stromal tissue. The specificity of the hybrid-
ization probe for INSL3was confirmed by the absence of
staining in the sense controls and by the specific staining
of Leydig cells in testis sections, a cell type known to abun-
dantly express INSL3 (2, 3).
Immunohistochemical localization of INSL3 protein
in ovary sections
The above quantitative PCR and in situ hybridization
data were further confirmed by immunohistochemical
staining of INSL3 protein. Figure 4B shows that the in-
tensity of staining for INSL3 was much greater in the TIC
layer, with little staining in theGC layer. The specificity of
the antibody for INSL3 was confirmed by the specific
staining of Leydig cells in testis sections.
In vitro TIC luteinization model
The effect of exposing cultured bovine TIC to a lutein-
izing dose of LH on INSL3 and RXFP2 expression was
examined. LH treatment for 4 days resulted in amore than
100-fold increase (P  .001) in the amount of progester-
one secreted by the cells and a corresponding increase in
the relative expression of transcripts for STAR (P .001)
and P450SCC (P  .05), indicative of functional lutein-
ization (Figure 5). In contrast, LH-induced luteinization
was associated with a marked decrease in the secretion of
INSL3 protein (P .01) and relative
abundance of INSL3 and RXFP2
transcripts (P  .01 and P  .001,
respectively).
Plasma steroid and INSL3
profiles during PG-synchronized
estrous cycles
Figure 6 showsmeandaily plasma
hormone profiles from5 heifers (n
15 cycles) sampled during PG-syn-
chronized estrous cycles. Repeated
measures ANOVA revealed a signif-
icant variation over time in plasma
INSL3, E2, and P4 (P  .001),
whereas plasma androstenedione
levels did not vary significantly (P
.35). As expected, P4 levels fell
steeply after PG, remaining low until
Figure 2. Correlation between the relative abundance of INSL3 and
cytochrome P450 17 alpha hydroxylase/17,20 lyase (CYP17A1) mRNA
transcripts in the theca interna layer of developing antral follicles of
1-18 mm in diameter (n  47); r  0.81, P  .0001.
Figure 3. Comparison of the relative abundance of INSL3 and RXFP2 mRNA transcripts in
bovine CL tissue. CL tissue was divided into early (n  4), mid (n  5), and late (n  3) phase
according to its morphology. Values are means (	SEM), and means indicated with different
letters are significantly different (P  .05).
doi: 10.1210/en.2012-2232 endo.endojournals.org 1901
day 6 when the new CL was forming. Plasma E2 levels
increased after PG induced luteolysis (d 0) and peaked on
day2–3, shortlybefore thepreovulatoryLHsurge (d3.5	
0.6). INSL3 levels followed a similar pattern to E2, in-
creasing by 38% (P  .05) from 62.9 pg/mL on day 0 to
86.6 pg/mL on day 2. Levels then fell by 54% to 39.8
pg/mL on day 4 (P  .001), coincident with the post-LH
surge decline in E2.
Does E2 directly alter
expression of INSL3 or RXFP2 by
nonluteinized TIC?
Given the above in vivo observa-
tion, we examinedwhether E2 could
directly affect expression of INSL3
or its receptor RXFP2 by isolated
TIC cultured under nonluteinizing
conditions. As shown in Figure 7,
treatment with E2 promoted a mod-
est increase in androstenedione se-
cretion (50%; P .05) but did not
affect the relative abundance of
INSL3 or RXFP2 transcripts.
Discussion
INSL3-null female mice have been
shown to display impaired fertility
(5, 17). However, there is a paucity
of data regarding the ovarian expres-
sion pattern and potential role(s) of
Figure 5. Changes in (A) progesterone and INSL3 levels in conditioned media and (B) relative
abundance of mRNA transcripts for steroidogenic acute regulatory protein (STAR), CYP11A1,
INSL3, and RXFP2 in bovine theca cells cultured 4 days with or without a luteinizing dose level of
LH (1.5 ng/mL). Values are means (	SEM), and statistical analysis was performed by
ANOVA.*P  .05, **P  .01, ***P  .001 (n  4 independent culture experiments).
Figure 4. Localization of INSL3mRNA (in situ hybridization; blue staining) (A and E) and INSL3 protein (immunohistochemistry; brown staining) (C and
G) in sections of bovine ovary (A–D) and testis (E–H) showing abundant expression in theca cells and Leydig cells, respectively. (B, D, F, and H)
Corresponding control sections incubated with sense riboprobe or nonimmune serum. a, antrum; g, granulosa layer; t, thecal layer. Scale bar, 100 m.
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INSL3-RXFP2 signaling in follicle development, steroido-
genesis, and CL function. Given reports that the ovarian ex-
pression of INSL3 is considerably higher in ruminants than
in nonruminant mammals (11, 18), in the first part of this
study, we used real-time PCR to quantify the patterns of
RNA expression for INSL3 and its receptor RXFP2 in the
theca interna and granulosal compartments of developing
bovine antral follicles and in early, midluteal, and regressing
CL. Overall, the relative abundance of INSL3 mRNA was
found tobemuchgreater inTIC thanGC,anobservationwe
confirmed by both in situ hybridization and by immunohis-
tochemistry demonstrating expression at the translated pro-
tein level. This finding is consistent with previous studies
showing that INSL3 is expressed predominantly byTIC (11,
14,18).Ourcomparisonof folliclesofvarious size categories
rangingfrom1–2to11–18mmrevealedfor thefirst timethat
INSL3 expression increases progressivelywith follicle devel-
opment, peaking in preovulatory stage follicles of 11–18
mm. Furthermore, when follicles of this size category were
subdivided according to their E2 to P4 ratio (34), the INSL3
transcript level was significantly lower (50%) in the estro-
gen-inactive follicles (presumed to be regressing) than in the
estrogen-active follicles (presumed to be healthy). The latter
observation is consistent with an earlier report (14) that
INSL3 expression levels were significantly decreased in at-
retic follicles. In the same study, pro-INSL3 protein was de-
tected by immunohistochemistry in 100%of the small mor-
phologically healthy follicles (2–5mm) but in only 57% of
morphologically healthy preovulatory follicles (12–17
mm) examined. It is unclear whether
an absence of detectable staining re-
flects the limit of sensitivity of the
method used or a genuine absence of
translated INSL3 protein. A detailed
immunohistochemical analysis of
INSL3 expression at the protein level
in follicles at different stages of de-
velopment was beyond the scope of
the present study.
We also found that expression of
RXFP2, the cognate receptor for
INSL3, was also substantially
(50-fold) higher in the thecal than
granulosal compartment. More-
over, thecal RXFP2 expression,
like INSL3, showed a marked and
progressive increase during follicle
maturation. In contrast to INSL3
levels, however, RXFP2 levels
peaked in 9- to 10-mm follicles, be-
fore declining approximately
5-fold in larger (11-18 mm) folli-
cles, regardless of their estrogenic status. These novel
findings on the intrafollicular distribution and pattern
of change of INSL3 and RXFP2 expression support the
concept that theca-derived INSL3 functions primarily
as an autocrine/paracrine regulator of theca cell func-
tion. However, given that a substantial fall in RXFP2
mRNA level was evident in large estrogen-active (11–18
mm) follicles expressing the highest levels of INSL3
mRNA, this might imply that INSL3-RXFP2 signaling
is actuallymaximal in the smaller 9- to 10-mm size class.
Interestingly, acquisition of LH receptors by GC only
occurs in bovine follicles growing beyond about 9 mm
in diameter (35, 36), presaging their transition into es-
trogen-active preovulatory follicles capable of trigger-
ing, and ovulating in response to, an LH surge (37, 38).
Because estrogen-active preovulatory follicles have the
greatest requirement for theca-derivedandrogenas an essen-
tial substrate for cytochrome P450 aromatase (39), one
might expect that regulatory mechanisms conducive to sus-
tained (or heightened) thecal androgen production would
prevail in preovulatory follicles. Indeed, as reviewed else-
where (40), a plethoraof local factors havebeen identified as
positive regulators of thecal androgen production, including
IGF (41,42), inhibin (43-45), andE2 itself (45, 46), the latter
2 produced in greatest amounts by GC of preovulatory fol-
licles. Conversely, other intraovarian factors, including
TGF- (47), activins (44, 48), bonemorphogenetic proteins
(22, 24, 49), TNF- (50), epidermal growth factor, and
TGF- (51), have been shown to suppress androgenproduc-
Figure 6. Changes in mean (	SEM) plasma concentrations of (A) E2, (B) progesterone, (C)
androstenedione, and (D) INSL3 during PG-synchronized/shortened estrous cycles in heifers.
Samples are aligned to the time of PG administration (d 0) indicated by the arrow. The mean
(	SEM) time of the LH surge (d 3.5 	 0.6) is indicated by the open square symbol. Statistical
analysis was performed by repeated measures ANOVA.
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tion. This begs the question: Is there any evidence that
INSL3-RXFP2 signaling contributes to the autocrine/para-
crine regulation of thecal androgen production?
The much higher levels of expression of both INSL3
and its receptor in the theca interna compartment in com-
parison with granulosal and luteal tissue suggest that
INSL3 acts in an autocrine/paracrine manner within the
follicle, being both predominantly produced by and acting
upon TIC. In the male, an autocrine role for INSL3 has
recently been described in mice, where both INSL3 and
RXFP2 were found to be expressed in testicular Leydig
cells. Treatment of cultured Leydig cells with INSL3 was
found to stimulate testosterone and cAMP secretion (52).
In the present study, INSL3 mRNA expression was pos-
itively correlated with CYP17A1 expression, whose gene
product (cytochromeP45017- hydroxylase/17,20 lyase)
is a key enzyme responsible for conversion of progestins to
androgens. Furthermore, in our cultured TIC model, ad-
dition of a luteinizing dose of LH, known to suppress
androgen production by ovarian theca cells (53, 54), dra-
matically increased expression of STAR and CYP11A1
mRNA and raised progesterone secretion concomitantly
with reduced INSL3 secretion and reduced expression of
INSL3 and RXFP2mRNA. In addition, we have recently
demonstrated (30) that RNA interference-mediated
knock downof either INSL3 orRXFP2 expression in non-
luteinized bovine TIC promotes a marked reduction in
CYP17A1 expression and androstenedione secretion.
Collectively, these observations reinforce the notion that
INSL3 is positively associated with follicular androgen
production. Indeed, recent studies have found that INSL3
is elevated in the plasma of women with polycystic ovary
syndromeand that levels inwomenwith this syndromeare
associated with ovarian hyperandrogenism (13, 20, 55).
INSL3 expression by bovine CL has been reported pre-
viously (11, 18, 21), but expression of its receptorRXFP2
was not documented in these reports. In the present study,
both INSL3 and RXFP2 mRNAs were detected in CL,
although relative expression levels (normalized to-actin)
were, respectively, more than 10- andmore than 100-fold
lower than in TIC, perhaps indicating that functional
INSL3-RXFP2 signaling is only weakly operational in CL
tissue. Consistent with previous studies (11, 18), mean
INSL3mRNA level was greatest in midluteal samples but
declined more than 10-fold in regressing CL.
To corroborate the above findings of 1) increased TIC
expression of INSL3 during antral follicle development, 2)
reduced INSL3 mRNA expression in luteal tissue, and 3)
reduced INSL3 expression in TIC luteinized in vitro by ex-
posure tohigh levels of LH,weusedournovel bovine INSL3
immunoassay (21) to monitor, for the first time, circulating
levels during PG-synchronized estrous cycles in cattle. We
found a significant cyclic variation in plasma INSL3 concen-
trations during the bovine estrous cycle, with INSL3 follow-
ing a similar profile to E2, increasing to maximal levels ap-
proximately 2 days after PG-induced luteolysis but then
falling sharply after the ovulation-inducing LH surge on day
3–4 after PG injection. As expected, P4 fell steeply after PG
induced luteolysis and did not rise again until 7 days later
when anewCLwas forming from thepostovulatory follicle.
It is notable that INSL3 levels did not fall in tandemwith P4
after luteolysis, or rise with P4 during formation of the new
CL.This further supports our finding that INSL3 is predom-
inantly expressed by follicular theca interna cells of healthy
preovulatory follicles, with much lower expression by CL.
Taken together, these results strongly support the view that
circulating INSL3 is a good biomarker for antral follicle de-
velopment, at least during the first wave of a synchronized
Figure 7. Lack of effect of E2 treatment (500 ng/mL) on relative
expression of INSL3 and RXFP2 mRNA by bovine theca interna cells
cultured in the presence of a nonluteinizing concentration of LH (150
pg/mL). Note that E2 significantly increased androstenedione secretion.
Values are means, and bars indicate SEM (n  4 independent cultures).
*P  .05 versus control.
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cycle. In agreement with the finding of others (56, 57),
plasmaandrostenedione levelsdidnotvary significantlydur-
ing the cycle, presumably because considerable amounts of
the steroid present in the circulation emanate from follicles
other than the dominant preovulatory follicle, and because
some androstenedione is aromatized to estrogen. Further,
some of the androstenedione in peripheral blood plasma is
likely to be of adrenal origin. Finally, our observation that
plasma INSL3 and E2 levels followed a similar profile after
PG-induced luteolysis prompted us to examine whether di-
rect exposureof cultured theca cells toE2, at a concentration
comparable with intrafollicular concentrations in preovula-
tory follicles, couldup-regulate INSL3expression.Although
E2 promoted a modest increase in androstenedione secre-
tion, consistent with previous reports for cattle and human
theca cells (45, 58), there was no effect on expression of
INSL3 or its receptor. Therefore, it remains to be investi-
gated what the signal(s) are that lead to increased thecal
INSL3 expression during the latter stages of follicle
development.
In conclusion, we have shown that much higher levels of
INSL3 are produced by TIC than by the GC or CL and that
expression levels increase progressively throughout antral
follicle development.Moreover, follicular theca interna cells
are the likely site of both production and action of INSL3
within the ovary. Our data indicate that cyclic changes in
predominantly theca-derivedINSL3,rather thanCL-derived
INSL3, likely from the dominant preovulatory follicle, are
detectable in peripheral blood of cattle. Both in vitro and in
vivo studies indicate that the expression of INSL3 is down-
regulated during luteinization induced by the preovulatory
LHsurge.Thepositive correlationobservedbetween INSL3
and CYP17A1 expression firmly indicates that INSL3 pro-
duction within the ovary is linked to androgen production.
Further investigation into the modulatory effects of INSL3
onthecal steroidogenesiswillbeofconsiderable interest,par-
ticularly in thecontextofovarianandrogenexcessassociated
with conditions such as polycystic ovary syndrome.
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